Skip to main content
Erschienen in: Rheumatology International 12/2013

01.12.2013 | Original Article

Regulatory T cells in Behçet’s disease: Is there a correlation with disease activity? Does regulatory T cell type matter?

verfasst von: Eren Gündüz, Hava Üsküdar Teke, Nazife Şule Yaşar Bilge, Döndü Üsküdar Cansu, Cengiz Bal, Cengiz Korkmaz, Zafer Gülbaş

Erschienen in: Rheumatology International | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to investigate the percentage of regulatory T cells and the correlation with clinical activity in Behçet’s disease. Forty Behçet’s disease (BD) patients, 18 males and 22 females, were included in the study. The patients were diagnosed according to the published BD criteria. Twenty age- and sex-matched volunteer healthy donors were also included. At the time of sampling, clinical activity was assessed for activity signs and symptoms according to the BD Current Activity Form. We considered active those patients with a clinical activity index equal to and/or above 2. Eleven patients had active disease and the remaining were considered as clinically inactive. We have studied the percentages of CD4+CD25+FOXP3+, CD4+CD25+ and CD4+FOXP3+regulatory T cells by flow cytometry and investigated the correlation with disease activity. Percentage of CD4+CD25+FOXP3+Treg in active patients was lower than clinically inactive patients and healthy controls. Percentage of CD4+CD25+Treg was not different between active and inactive patients and healthy controls. Percentage of CD4+FOXP3+Treg was lower than healthy controls in clinically active patients but was not different for inactive group and healthy controls. Patients were active when CD4+CD25+FOXP3+Treg was ≤1.19 %, CD4+CD25+Treg was ≤2.68 %, and CD4+FOXP3+Treg was ≤2.60. CD4+CD25+FOXP3+Treg and CD4+FOXP3+Treg were found negatively correlated with disease activity. Peripheral blood regulatory T cells are decreased in clinically active Behçet’s disease patients. The advances in our understanding of the interactions between distinct subsets of Treg and clinical activity might help in modulating BD treatment.
Literatur
1.
Zurück zum Zitat Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behçet’s disease. N Engl J Med 341:1284–1291PubMedCrossRef Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behçet’s disease. N Engl J Med 341:1284–1291PubMedCrossRef
2.
Zurück zum Zitat McGonagle D, McDermott MF (2006) A proposed classification of the immunological diseases. PLos Med 3:1242–1248CrossRef McGonagle D, McDermott MF (2006) A proposed classification of the immunological diseases. PLos Med 3:1242–1248CrossRef
3.
Zurück zum Zitat Andersson J, Tran DQ, Pesu M, Davidson TS, Ramsey H, O’Shea JJ et al (2008) CD4+FoxP3+regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med 205:1975–1981PubMedCrossRef Andersson J, Tran DQ, Pesu M, Davidson TS, Ramsey H, O’Shea JJ et al (2008) CD4+FoxP3+regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med 205:1975–1981PubMedCrossRef
4.
Zurück zum Zitat McMurchy AN, Bushell A, Levings MK, Wood KJ (2011) Moving to tolerance: clinical application of T regulatory cells. Sem Immunol 23:304–313CrossRef McMurchy AN, Bushell A, Levings MK, Wood KJ (2011) Moving to tolerance: clinical application of T regulatory cells. Sem Immunol 23:304–313CrossRef
5.
Zurück zum Zitat International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080 International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080
6.
Zurück zum Zitat Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ (1999) Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology 38:728–733PubMedCrossRef Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ (1999) Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology 38:728–733PubMedCrossRef
7.
Zurück zum Zitat deChambrun MP, Wechsler B, Geri G, Cacoub P, Saadoun D (2012) New insights into the pathogenesis of Behçet’s disease. Autoimmune Rev 11:687–698CrossRef deChambrun MP, Wechsler B, Geri G, Cacoub P, Saadoun D (2012) New insights into the pathogenesis of Behçet’s disease. Autoimmune Rev 11:687–698CrossRef
8.
Zurück zum Zitat Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+regulatory T cells. Nat Immunol 4:304–306CrossRef Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+regulatory T cells. Nat Immunol 4:304–306CrossRef
9.
Zurück zum Zitat Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R et al (2007) Activation induced Foxp3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 19:345–354PubMedCrossRef Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R et al (2007) Activation induced Foxp3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 19:345–354PubMedCrossRef
10.
Zurück zum Zitat Nanke Y, Kotake S, Goto M, Ujihara H, Matsubara M, Kamatni N (2008) Decreased percentages of regulatory T cells in peripheral blood of patients with Behçet’s disease before ocular attack: a possible predictive marker of ocular attack. Mod Rheumatol 18:354–358PubMedCrossRef Nanke Y, Kotake S, Goto M, Ujihara H, Matsubara M, Kamatni N (2008) Decreased percentages of regulatory T cells in peripheral blood of patients with Behçet’s disease before ocular attack: a possible predictive marker of ocular attack. Mod Rheumatol 18:354–358PubMedCrossRef
11.
Zurück zum Zitat Hamzaoui K, Borhani Haghighi A, Ghorbel IB, Houman H (2011) RORC and Foxp3 axis in cerebrospinal fluid of patients with neuro-Behçet’s disease. J Neuroimmunol 50:249–253CrossRef Hamzaoui K, Borhani Haghighi A, Ghorbel IB, Houman H (2011) RORC and Foxp3 axis in cerebrospinal fluid of patients with neuro-Behçet’s disease. J Neuroimmunol 50:249–253CrossRef
12.
Zurück zum Zitat Pekiner FN, Aytugar E, Demirel GY, Borahan MO (2012) Interleukin-2, interleukin-6 and T regulatory cells in peripheral blood of patients with Behçet’s disease and recurrent aphthous ulcerations. J Oral Pathol Med 14:73–79CrossRef Pekiner FN, Aytugar E, Demirel GY, Borahan MO (2012) Interleukin-2, interleukin-6 and T regulatory cells in peripheral blood of patients with Behçet’s disease and recurrent aphthous ulcerations. J Oral Pathol Med 14:73–79CrossRef
13.
Zurück zum Zitat Hamzaoui K (2007) Paradoxical high regulatory T cell activity in Behçet’s disease. Clin Exp Rheumatol 25:107–113 Hamzaoui K (2007) Paradoxical high regulatory T cell activity in Behçet’s disease. Clin Exp Rheumatol 25:107–113
14.
Zurück zum Zitat Hamzaoui K, Hamzaoui A, Houman H (2006) CD4+CD25+regulatory T cells in patients with Behçet’s disease. Clin Exp Rheumatol 24:71–78 Hamzaoui K, Hamzaoui A, Houman H (2006) CD4+CD25+regulatory T cells in patients with Behçet’s disease. Clin Exp Rheumatol 24:71–78
15.
Zurück zum Zitat Geri G, Terrier B, Rosenzwajg M, Wechsler B, Touzot M, Seilhean D et al (2011) Critical role of IL-21 in modulating T(H)17 and regulatory T cells in Behçet’s disease. J Allergy Clin Immunol 128:655–664PubMedCrossRef Geri G, Terrier B, Rosenzwajg M, Wechsler B, Touzot M, Seilhean D et al (2011) Critical role of IL-21 in modulating T(H)17 and regulatory T cells in Behçet’s disease. J Allergy Clin Immunol 128:655–664PubMedCrossRef
16.
Zurück zum Zitat Liang L, Wang H, Peng XY, Zhao M (2011) The changes of Th lymphocyte subsets in patients with Behcet disease. Zhonghua Yan Ke Za Zhi 47:393–397PubMed Liang L, Wang H, Peng XY, Zhao M (2011) The changes of Th lymphocyte subsets in patients with Behcet disease. Zhonghua Yan Ke Za Zhi 47:393–397PubMed
17.
Zurück zum Zitat Mochizuki M, Morita E, Yamamoto S, Yamana S (1997) Characteristics of T cell lines established from skin lesions of Behçet’s disease. J Dermatol Sci 15:9–13PubMedCrossRef Mochizuki M, Morita E, Yamamoto S, Yamana S (1997) Characteristics of T cell lines established from skin lesions of Behçet’s disease. J Dermatol Sci 15:9–13PubMedCrossRef
18.
Zurück zum Zitat Sugita S, Yamada Y, kaneko S, Horie S, Mochizuki M (2011) Induction of regulatory T cells by infliximab in Behçet’s disease. IOVS 52:476–484 Sugita S, Yamada Y, kaneko S, Horie S, Mochizuki M (2011) Induction of regulatory T cells by infliximab in Behçet’s disease. IOVS 52:476–484
19.
Zurück zum Zitat Bluestone JA (2005) Regulatory T cell therapy: is it ready for the clinic? Nat Rev Immunol 5:343–349PubMedCrossRef Bluestone JA (2005) Regulatory T cell therapy: is it ready for the clinic? Nat Rev Immunol 5:343–349PubMedCrossRef
20.
Zurück zum Zitat Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J et al (2004) In vitro expanded antigen specific regulatory T cells suppress autoimmune diabetes. J Exp Med 199:1455–1465PubMedCrossRef Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J et al (2004) In vitro expanded antigen specific regulatory T cells suppress autoimmune diabetes. J Exp Med 199:1455–1465PubMedCrossRef
21.
Zurück zum Zitat Furtado GC, Olivares-Villagomez D, Curotto de Lafaille MA, Wensky AK, Latkowski JA, Lafaille JJ (2001) Regulatory T cells in spontaneous autoimmune encephalomyelitis. Immunol Rev 182:122–134PubMedCrossRef Furtado GC, Olivares-Villagomez D, Curotto de Lafaille MA, Wensky AK, Latkowski JA, Lafaille JJ (2001) Regulatory T cells in spontaneous autoimmune encephalomyelitis. Immunol Rev 182:122–134PubMedCrossRef
22.
Zurück zum Zitat Shim J, Lee ES, Park S, Bang D, Sohn S (2011) CD4+CD25+regulatory T cells ameliorate Behçet’s disease like symptoms in a Mouse model. Cytotherapy 13:835–847PubMedCrossRef Shim J, Lee ES, Park S, Bang D, Sohn S (2011) CD4+CD25+regulatory T cells ameliorate Behçet’s disease like symptoms in a Mouse model. Cytotherapy 13:835–847PubMedCrossRef
Metadaten
Titel
Regulatory T cells in Behçet’s disease: Is there a correlation with disease activity? Does regulatory T cell type matter?
verfasst von
Eren Gündüz
Hava Üsküdar Teke
Nazife Şule Yaşar Bilge
Döndü Üsküdar Cansu
Cengiz Bal
Cengiz Korkmaz
Zafer Gülbaş
Publikationsdatum
01.12.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 12/2013
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-013-2835-8

Weitere Artikel der Ausgabe 12/2013

Rheumatology International 12/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.